Press Room

Press Clipping / Dec 10, 2018

Life Sciences: Hovione increases production capacity while looking forward to its tenth year in Cork

Irish Examiner, December 10, 2018

2019 will be a very significant year for Hovione the contract pharmaceutical manufacturing company which helps bring new and off-patent drugs to market celebrates 10 years Irish-side.

Hovione which took over Pfizer’s former Loughbeg site in Ringaskiddy in 2009 has seen rapid growth over the last 10 years.

The company employs over 200 people in Cork and hundreds more at its other three sites spread over three continents with facilities in Lisbon (Portugal), Macau (China), New Jersey (USA).

Hovione has over 55 years of experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates.

The Cork plant plays a significant and strategic role within the Hovione network and that was certainly proven earlier this year when Hovione expanded its production capacity.

Having recommissioned a third production building at their site in Ringaskiddy Hovione went into production at this building in May of this year.

“This is the first time in Cork’s history that all three buildings have been running at the same time”, said General Manager Paul Downing who said it is an exciting time in the company’s history as Hovione Cork now have extensive manufacturing capacity with two Active Pharmaceutical Ingredient facilities alongside a Drug Product Intermediate facility that houses the largest, commercial pharmaceutical spray dryer in operation.

Dr Downing said he is optimistic about the future.

2019 he said is going to be a really big year for Hovione Worldwide as it celebrates its 60th Anniversary. 

The company was founded by Ivan Villax with his wife Diane Villax in Lisbon in Portugal in 1959.

“We have a very ambitious plan to be the Number 1 innovative, integrated pharmaceutical solution provider to the global pharmaceutical industry by 2028,” said Dr Downing. 


Our mission is to passionately turn any challenge into a solution by collaboration with our partners to develop great medicines.


"That is a company corporate goal so that requires all our facilities to grow and expand so this expansion plan is across the whole Hovione network including Lisbon, New Jersey, Macau and also obviously Cork.

“In short we give our customers what they cannot find elsewhere”, says Dr. Downing, who explains that the company’s customers come from the sectors of biotechnology, medium, speciality and large pharmaceuticals as well as generics pharmaceuticals.

“Hovione has a unique value proposition. We have more than 15 years of experience in pharmaceutical spray drying and have produced hundreds of batches for clinical trials and commercial supplies.

“We have a very diverse workforce. We currently have 15 nationalities onsite here in Cork. 

"Hovione is a fast, challenging dynamic environment and there are great opportunities for people with all skill sets at whatever age.

“Because the market demands different products you can work on multiple products and multiple projects at the same time. That gives people a diversity of experience. 

"We like to have a balance between promoting from within and recruiting from outside so therefore if someone has the desire to move within the organisation these opportunities arise.”

Hovione is constantly developing its talent pool and is a big supporter of and encourages apprenticeships for young people where they get an opportunity to gain very substantial and important skills allowing them to take up roles as electricians, fitters, quality control analysts, instrument technicians as well as automation technicians.

The Apprenticeship programme not only provides participants with the necessary technical and professional skills, it also provides valuable teamwork experience.

Valuable teamwork experience

“What we do find is that people can have very strong technical and academic skills but their team collaboration skills require us to invest in further training. 

"These skills would be automatically instilled in participants in the Apprenticeships programmes. 


In complex and large organisations like ourselves the interpersonal skills and an ability to work in small teams is important.


Hovione works with Skillsnet and other local academic institutions to help build capabilities that can take advantage of the many career opportunities available.

“We do College site tours and Master student placements. We work with the IDA on the IBEC EOP Programme which sees graduates spend six months with us and six months with our sister facility in Portugal mostly working as process engineers or QC analysts. 

"We hope these graduates will come and join us in our new process in Cork in 2019.

“We continue to work with the Portuguese Postdoctoral Graduate Placement Programme and with the Cork Education Training Board and this year we supported the IBEC Laboratory Apprenticeship Programme — we have the first two apprentices joining from that initiative this January in collaboration with CIT so we look forward to that as it has been a couple of years in the making.”

Overall, Hovione’s steadfast growth is the result of an integrated synergy that allows the company to serve both the global markets and also to respond to specific customer demands when necessary.

The company has a solid legacy of Corporate Social Responsibility — last year Hovione became a Certified B Corp – becoming the first facility in Ireland to have received this certification.

The company’s ‘Safety First, Quality Always’ culture is also something staff are very proud of - “we nurture it each day so that we do not take it for granted”.

“In the coming years we will continue to invest in additional capability and hire additional team members, launch and validate more new products”, says Dr Downing, who points out that the company is an active member of Biopharmachem Ireland, Cork Chamber as well as Business in the Community Ireland.

Hovione sponsors and supports local community initiatives as well as establishing crucial links with the academic and training institutions through its support of STEM — initiatives to encourage take-up of subjects such as science, technology, engineering and mathematics — as well as CIT Student placements and the Cork Training Centre.

Just last week, Hovione won the Corporate Citizen Responsibility Business in Community Ireland Mark.

Carbon footprint commitment

“We are one of 40 leading companies who have signed up to significantly reduce their carbon emissions between now and 2030”.

The pledge was made at a summit organised in Dublin last week by Business in the Community in Ireland, which describes itself as a network for sustainability.

“We are the first contact manufacturing organisation to win that award,” said Dr Downing. 

“We see that things like corporate social responsibility, being ethical in the workplace and within the community, reducing our carbon footprint are all important very important issues going forward.”

Hovione committed to engaging with its local communities

Hovione holds annual corporate social responsibility days and each year a particular organisation is chosen.

This year, the company supported SIMON Community — fundraising and giving practical support. Every Christmas, the company also facilitates food and gift appeals for the Society of St Vincent de Paul.

Dr Paul Downing said: “We are the first chemical / pharmaceutical company integrating this innovative community of companies that use the power of business to solve social and environmental problems. 

"As a Certified B Corporation, we want to contribute to redefine success in business meeting the highest standards of social and environmental performance, setting out Team Members for success and personal satisfaction and aspiring to use the power of markets to solve social and environmental problems.


This is a global movement of people using business as a force for good, with a vision that one day all companies compete not only to be the best in the world but the best for the world.


As well as expansion in Cork, Hovione is completing by the end of 2018 the qualification of its continuous tableting line at New Jersey (USA)

The capacity expansion program started in 2016 and will continue in the coming five years. 

Hovione has relocated its development services to a new centre with 7,000 m2 in Lisbon — fully equipped with the most recent tools to handle potent and highly potent compounds.

The Loures site expanded its drug substance reaction vessel capacity with a small-scale production area and a new pilot plant. 

The company installed more spray drying capacity at the site and started the operation of a new drug product centre equipped with oral dosage form as well as inhalation manufacturing capabilities. 

In New Jersey, Hovione has doubled the size of its development and manufacturing operations.

The decision to expand follows growing customer demand since Hovione started offering end-to-end solutions from drug substance to drug product from the Loures site in 2017.

Hovione increased production capacity in oral dosage forms in Portugal to strengthen their integrated offering. 

New commercial scale equipment for blending, tableting and coating will complement existing development small scale equipment. 

This ‘One Site Shop’ allows customers to streamline their supply chain, reduce time to market and benefit from seamless project management. 

This increase in capacity helps Hovione customers to consistently bring products to market faster.

Paul looks forward to a very exciting year ahead. 

All these successes here at home, he says, would not have been possible without the continued support of the local businesses, IDA, Biopharmachem Ireland and the staff working at the Cork facility.

 

Read the full article

 

Also in the Press Room

See All

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Today marks the start of CPhI Frankfurt, a huge trade show in Germany focused on the supply of pharmaceutical ingredients and other services to the drug industry. C&EN editor in chief Nick Perkins, life sciences editor Laura Howes, and reporter Aayushi Pratap are all there to meet drug outsourcing executives and take the pulse of the sector. In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active pharmaceutical ingredients. And the Portuguese pharmaceutical services firm Hovione says it has completed a $100 million investment in New Jersey (story below). (...) Hovione invests in spray-drying in New Jersey The pharmaceutical services firm Hovione says it has spent $100 million to expand its operation in East Windsor, New Jersey. The facility spray-dries drug ingredients to create amorphous solid dispersions, which improve solubility and bioavailability. The Portuguese company says the new spray dryers will begin operating in the second quarter of 2026. The New Jersey facility opened in 2002, making Hovione one of the longest-established European pharmaceutical services firms in the US, CEO Jean-Luc Herbeaux says in a press release. Hovione says it has purchased land adjacent to the East Windsor site on which it can add new facilities for services such as spray-drying and drug tableting. Hovione is also investing at its sites in Ireland and Portugal. —Michael McCoy   Read the full article at CEN.acs.org  

Press Clipping

Oct. 28 Business Watch: More plants closing in Europe, Novartis to pay $12 billion for biotech firm

Oct 28, 2025

Developing drugs with poor water solubility remains a major challenge for pharmaceutical manufacturers, because solubility impacts bioavailability and effective drug delivery. The vast majority of small molecule drug candidates have low water solubility. For more than two decades, the most successful particle engineering technology to improve drug solubility and bioavailability has been spray drying with an amorphous solid dispersion (ASD) platform. Spray drying improves the solubility of oral drugs, inhalable particles, and excipients, and increases the stability of heat-sensitive drug products. Hovione, recognized globally for its industry-leading spray drying capabilities, has recently completed a $100 million investment cycle to enhance its operations in New Jersey. This initiative has successfully doubled Hovione’s spray-drying capacity in the US, strengthening its position in the industry. Hovione’s Expanded U.S. Site in East Windsor, NJ  The first phase of the expansion in East Windsor, NJ, delivers a new 31,000 square foot facility and houses two size-3 spray dryers (PSD-3). This additional capacity allows Hovione to meet increasing customer demand for ASD development and good manufacturing practice (GMP) commercial production. GMP operations are scheduled to commence in the second quarter of 2026.  Hovione has also acquired 15 acres of neighboring land, strategically positioning itself for future growth and evolving customer needs for U.S. manufacturing. The newly acquired greenfield site will provide future support for PSD-4–scale commercial production as well as continuous and batch tableting production. It will also be a hub for centralized logistics, enhanced quality control laboratories, and next-generation research and development facilities.  A Global CDMO with a Growing U.S. Footprint  Hovione has operated in New Jersey for more than two decades, establishing itself with a strong U.S. presence for the production of drug substances, intermediates, and finished drug products. A continued emphasis on an integrated service offering, including spray drying, supports delivering innovative medicines to patients more quickly.  The expansion of the East Windsor site addresses the rising demand for U.S. manufacturing and is an integral part of the company's ongoing global growth strategy, with facilities in Portugal, Ireland, and Macau. The company continues to bolster a cohesive network for drug development and commercial manufacturing unified by a corporate quality system and governance framework.  The integrated offering enhances development speed and eases technology transfers by unifying the team's technical skills, proprietary technologies, and digital platforms to efficiently produce drug substance to drug products at a single-site, through Hovione’s “one site, one partner” vision. Furthermore, Hovione’s strategic partnership model offers customers exclusive access to advanced technologies and resources while aiding in the optimization of their development programs and ensuring sustained value creation.  End-to-End Spray Drying and Particle Engineering: From Grams to Tons Hovione is a global leader in spray drying and particle engineering. Services include solubility enhancement and controlled-modified release via development and production of ASDs of both small and large molecules, supporting various modalities. ASD-HIPROS, Hovione’s proprietary spray drying screening platform, identifies optimal formulations that offer optimal performance and stability. By increasing production volume in the US, Hovione will meet customer demand for spray drying services:  Development services in the laboratory (1 g – 1 kg batches)  Pilot scale production (0.5 – 25 kg batches)  Small-scale production (5 – 200 kg batches)  Large-scale commercial manufacturing (50 – 400 kg batches) A Commitment to Sustainability  Hovione’s core values include a commitment to sustainability at all facilities. This commitment is reflected in a business strategy that focuses on improving the communities where the company operates. Hovione’s sustainability policy and strategy align with the UN Sustainable Development Goals and include adherence to science-based targets in line with the Paris Agreement to address climate change. Meeting these goals has required a dedication to process intensification and ensuring sustainability of manufacturing processes. This has been possible through strategic planning and commitments from senior management to ensure sustainability is addressed throughout the drug development life cycle.  Partner with a Technology-Leading CDMO for U.S. Manufacturing   As demand for poorly water-soluble drug formulations continues to rise in the U.S., expanding spray drying throughput is essential to meet the need for innovative therapeutics. With proven leadership in spray drying to manufacture ASDs, Hovione is able to support pharmaceutical companies by solving their solubility challenges efficiently and reliably.  Partnering with a CDMO that combines global leadership, advanced technologies, and the necessary manufacturing capacity in the U.S., drug developers can expedite time to market, ensure quality, and deliver innovative medicines to patients faster.  If your company is seeking access to the latest spray-drying capabilities, expanded U.S. manufacturing capacity, and an accelerated path to regulatory filing and commercialization, contact our team today.     

News

Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing

Oct 27, 2025